Table 3.
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients.
| Best overall response | 1L AML (N = 22) | 1L MDS (N = 24) |
|---|---|---|
| ORR | 14 (64%) | 22 (92%) |
| CR | 9 (41%) | 15 (50%) |
| CRi | 3 (14%) | – |
| PR | 1 (5%) | 0 |
| MLFS/marrow CR | 1 (5%) | 8 (33%) [4 with marrow CR + HI] |
| HI | – | 2 (8%) |
| SD | 7 (32%) | 2 (8%) |
| PD | 1 (5%) | 0 |
ORR, objective response rate; CR, complete remission; CRi, complete remission with incomplete count recovery; PR, partial response; MLFS, morphologic leukemia free state; HI, hematologic improvement; SD, stable disease; PD, progressive disease. Responses were assessed according to 2017 European LeukemiaNet criteria for AML and 2006 International Working Group criteria for MDS. Data referenced was presented at the ASH annual meeting in 2019 (32).